Tue, December 4, 2012
Mon, December 3, 2012
Sun, December 2, 2012
Sat, December 1, 2012
Fri, November 30, 2012
Thu, November 29, 2012
Wed, November 28, 2012
Tue, November 27, 2012
Mon, November 26, 2012
Sun, November 25, 2012
Fri, November 23, 2012
Thu, November 22, 2012
Wed, November 21, 2012
Tue, November 20, 2012
Mon, November 19, 2012
Sat, November 17, 2012
Fri, November 16, 2012
Thu, November 15, 2012
Wed, November 14, 2012
Tue, November 13, 2012
Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012

Sarepta Therapeutics to Present Company Overview at the 2012 24th Annual Piper Jaffray Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. -annual-piper-jaffray-healthcare-conference.html
Published in Health and Fitness on Tuesday, November 20th 2012 at 5:46 GMT by Market Wire   Print publication without navigation


November 20, 2012 08:30 ET

Sarepta Therapeutics to Present Company Overview at the 2012 24th Annual Piper Jaffray Healthcare Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwire - Nov 20, 2012) -  Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2012 24th Annual Piper Jaffray Healthcare Conference in New York, NY on Tuesday, November 27, 2012 at 9:30 a.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

The audio presentation will be webcast live under the events section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources